General Information


We are a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology. Our product candidates are designed to address diseases with high unmet medical needs by pairing our PLEX technology with drugs already approved by the U.S. Food and Drug Administration, or FDA. Our PLEX technology is designed to deliver drugs directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. 

Employees: 57
Founded: 2008
Contact Information
Address 18 Hasivim Street, P.O. Box 7126, Petach Tikva 4959376 Israel
Phone Number +972 (74) 719-5700
Web Address http://www.polypid.com
View Prospectus: PolyPid
Financial Information
Market Cap $262.7mil
Revenues $0 mil (last 12 months)
Net Income $-6.9 mil (last 12 months)
IPO Profile
Symbol PYPD
Exchange NASDAQ
Shares (millions): 3.8
Price range $16.00 - $16.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Barclays/ BMO Capital Markets
CO-Managers Raymond James/ National Securities/ Oddo BHF/ A.G.P. (Alliance Global Partners)
Expected To Trade: 6/26/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change